The DOI matches its Crossref record.
Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
Abstract
The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18 F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k iocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The k iocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Mendez, I., Sanchez-Pernaute, R., Cooper, O., Viñuela, A., Ferrari, D., Björklund, L., Dagher, A., & Isacson, O. (2005) · Brain · doi:10.1093/brain/awh510 · Cited by 438
Functional Decline in Parkinson Disease
Jankovic, J., & Kapadia, A. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1611 · Cited by 427
Spatial Remapping of Cortico-striatal Connectivity in Parkinson's Disease
Helmich, R. C., Derikx, L. C., Bakker, M., Scheeringa, R., Bloem, B. R., & Toni, I. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp178 · Cited by 418
Advances in markers of prodromal Parkinson disease
Postuma, R. B., & Berg, D. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.152 · Cited by 405
Metadata
- Authors
- Nurmi, E., Ruottinen, H. M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., & Rinne, J. O.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 16
- Issue
- 4
- Pages
- 608-615
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2006375474
- Cited by
- 219
- References
- 0
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study. https://app.cochat.ai/papers/10.1002/mds.1139
- The paper
- Nurmi, E., Ruottinen, H. M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., & Rinne, J. O. (2001). Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study. Movement Disorders. https://doi.org/10.1002/mds.1139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.